Shots:
- BI has licensed a pre-clinical small molecule program from Kyowa Kirin to develop it as a potential treatment for autoimmune diseases
- As per the deal, BI will receive exclusive rights to develop the small molecule program globally, expanding BI’s inflammatory pipeline
- In contrast, Kyowa Kirin will receive up to €640M (~$744.4M), incl. an upfront payment, development, regulatory, & commercial milestone payments, with royalties on future sales
Ref: Boehringer Ingelheim| Image: Boehringer Ingelheim & Kyowa Kirin | Press Release
Related News:- Boehringer Ingelheim and Click Therapeutics Report P-III (CONVOKE) Trial Data on CT-155 for Schizophrenia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
